Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Access Lessons For Cell And Gene Therapies In Germany

Companies Can Learn From Bluebird Bio’s Failed Zynteglo Pricing Deal

Executive Summary

Lawyer and industry expert Alexander Natz sets out some important dos and don’ts for securing a successful launch of an advanced therapy in Germany.

You may also be interested in...



Dutch HTA Body Hits Out At Bluebird’s Zynteglo Pricing

The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.

Safety Thumbs Up For Zynteglo Prompts Bluebird To Lift Marketing Suspension

No evidence has been found linking the viral vector in bluebird’s gene therapy for β-thalassemia to blood cancer, the European Medicines Agency says.

Germany To Tackle Cell And Gene Therapy Funding Barriers

If approved, new legislation would allow hospitals to apply for funding for ATMPs before marketing authorization.

Related Content

Topics

UsernamePublicRestriction

Register

PS144234

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel